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Abstract The goal of the present study was to investigate
the action of TBBPA on PPARc protein expression in vitro
in human choriocarcinoma-derived placental JEG-3 cells.
We also analyzed TBBPA for its action on placental
secretion of progesterone and b-hCG, cell viability, and
apoptosis. Our results showed that after TBBPA treatment
at 10 nM and 10 lM, PPARc protein expression increased
in a time-dependent manner until 48 h and then slightly
decreased at 72 h but was still above the control level. This
alteration in PPARc protein expression was accompanied
by a decreased b-hCG level. Interestingly, co-treatment
with the PPARc antagonist GW9662 reversed the TBBPA-
mediated changes in PPARc protein expression but,
according to b-hCG secretion, potentiated an inhibitory
effect of TBBPA. Additionally, in our study, we assessed
the ability of TBBPA to increase progesterone levels in
JEG-3 cells compared with those of controls. Finally, in the
present study, we demonstrated that TBBPA at all of the
tested doses significantly increased caspase-3 activity
compared with that of the vehicle control. The apoptotic
action of TBBPA was also confirmed by Hoechst 33342
staining. These results showed the up-regulation of PPARc
protein expression after TBBPA exposure in human pla-
cental cells. Although co-treatment with antagonist of
PPARc reversed the TBBPA-mediated increase in this
protein expression and restored it to the control level, it did
not reverse the effect on b-hCG secretion. This indicated
that the mechanism of TBBPA-induced changes in b-hCG
secretion is PPARc-independent.
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Introduction
Tetrabromobisphenol A (TBBPA) is the highest selling
brominated flame retardant and has become a hazardous
environmental contaminant worldwide [1]. TBBPA is
released into the environment primarily through various
waste streams that are generated during manufacturing and
processing and upon disposal [2], but it also leaks out from
a variety of commercial products in our houses and cir-
culates as dust [3, 4]. This contamination represents a
potential to cause harm to human health. The number of
studies demonstrate endocrine disrupting effects for
TBBPA in both in vitro and in vivo tests [5–10].
The highly lipophilic character of this substance and,
thus, its ease of crossing cell membranes should be a matter
of great concern. Ogunbayo et al. [11] demonstrated the
ability of TBBPA to interact with phospholipid mem-
branes, restricting their motion, which in turn could mod-
ulate some cellular processes. Numerous epidemiological
studies have shown the presence of TBBPA in body fluids,
such as human blood [12–16] and breast milk [17–20].
Assuming a mean TBBPA concentration in breast milk of
0.073 ng/g fresh weight and an average daily intake of milk
by a breastfed newborn of 500 ml, the intake of TBBPA
can be estimated at 40 ng [17]. TBBPA has also been
detected in umbilical cords [17, 20–22] at concentrations
that are relevant to this study. Furthermore, the TBBPA
concentration was 2–5 times higher in the infants than in
the mothers [23], indicating maternal transport as a critical
factor for the exposure of a developing fetus to TBBPA.
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The presence of TBBPA in placenta tissue poses a
serious threat to the proper functions of the organ acting as
an endocrine gland, which consequently generates a risk
for pregnancy health and proper development of the fetus.
The human placenta is a highly specific endocrine gland
that is responsible for the synthesis of a number of hor-
mones and proteins that are necessary for normal fetal
development and pregnancy maintenance. Barak et al. [24]
demonstrated that peroxisome proliferator-activated
receptor c (PPARc) null mutant placentas exhibit vascular
anomalies with a failure in vascular labyrinth formation.
This experimental approach revealed a key role of PPARc
in placenta development. Since then, extensive studies
have considered PPAR’s control of placental biology. In
the human placenta, PPARc regulates trophoblast differ-
entiation and invasion which are essential for fetal devel-
opment and pregnancy maintenance [25–27]. Recent data
indicate that TBBPA can activate PPARc by acting as an
agonist in NIH3T3-L1 preadipocytes [28]. However, there
is no information available regarding the mechanism of
PPARc activation by TBBPA in the placenta cells and the
potential consequences of the process. Thus, the aim of the
present study was to investigate the capacity of TBBPA to
interact with and perturb signaling by PPARc. Thus the
aim of the present study was to investigate the effect of
TBBPA on placental hCG and progesterone secretion and




The human choriocarcinoma-derived placental JEG-3 cell
linewas obtained from theAmerican TypeCulture Collection
(Rockville, MD, USA). The cells were maintained in DMEM
without phenol red and were supplemented with 10 % char-
coal-stripped FBS (and thus depleted of steroid hormones),
100 UI/ml penicillin, and 100 lg/ml streptomycin in 75-cm2
cell culture flasks (Nunc, Denmark). JEG-3 cells were cul-
tured at 37 C in a humidified atmosphere of 5 % CO2/95 %
air.A confluent JEG-3 cell culturewas detached from theflask
with 0.25 % trypsin–EDTA and allowed to adhere in culture
plates for at least 24 h before treatment.
Cell exposure to chemicals
The cells were seeded in 96-well culture plates (Costar, St.
Louis, USA) at a density of 8 9 103 (for the 24-h treat-
ment), 7 9 103 (for the 48-h treatment) or 6 9 103 (for the
72-h treatment) and initially cultured for 24 h. Subse-
quently, in one experiment, the medium was changed to
DMEM that was supplemented with 5 % charcoal-stripped
FBS in the presence of TBBPA (1 nM, 10 nM, 50 nM,
100 nM, 1 lM, 10 lM, 50 lM, or 100 lM). In a second
experiment, the cells were pretreated with PPARc agonist
GW1929 (10 lM) or the PPARc antagonist GW9662
(10 lM) for 2 h prior to the addition of TBBPA (10 nM) at
the indicated time. GW1929 and GW9662 at this concen-
tration did not alter cell viability (data not shown). For
hormone analysis, the culture medium was collected after
48 h. Each stock solution of TBBPA, GW1929, and
GW9662 was made in DMSO as a 1000-fold stock solution
and stored at 4 C (TBBPA) or at -20 C (GW1929 and
GW9662). For cell exposure, the incubation media were
prepared through a 1000-fold dilution of the DMSO stock
solution with the culture medium (0.1 % vol/vol DMSO)
immediately prior to cell treating. At this concentration,
DMSO had no effect on steroid secretion or cell viability.
The viability of the cells was determined before seeding by
the Trypan blue exclusion test and was found to be C95 %
(data not shown). The control group was cultured in
medium with 0.1 % DMSO.
After an appropriate culture time, 100 ll of medium was
collected to test for cell viability, and the rest was frozen at
-20 C for hormone (progesterone and b-hCG) analyses.
The cells were frozen at -80 C and used for the estima-
tion of apoptosis (caspase-3 activity) as described below.
Every treatment was conducted in ten wells, and each
experiment was repeated three times.
Viability assay
The cytotoxic potential of TBBPA was determined by the
cytotoxicity detection kit (Roche Applied Science, Germany)
according to the manufacturer’s instructions. The assay is
based on the detection of lactate dehydrogenase (LDH) that is
released from dead cells as a result of cytotoxicity. Briefly,
after 24, 48, and 72 h of exposure to increasing doses of
TBBPA, 100 ll of the culture medium was transferred to
96-well microtiter plates, and the LDH activity was deter-
mined by the addition of the substrate solution. The formation
of formazan was measured at 492 nm in a microplate reader
(Bio-Tek ELx800). The data were analyzed with KCJunior
(Bio-Tek Instruments) andwere normalized to the absorbance
in vehicle-treated cells. The results were expressed as the
mean absorbance from thirty separate samples ± SEM. The
extinction values of the control cells were set as 100 %, and
the rate of LDH release from treated cells was calculated as a
percentage of the control.
b-hCG and progesterone secretion
The levels of placental hormones were measured to
determine the response curve to different TBBPA
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concentrations during various periods of exposure. The
amounts of b-hCG and progesterone were determined in
the media by an enzyme-linked immunosorbent assay
(ELISA) using commercial kits (DRG, Marburg, Germany)
according to the manufacturer’s instructions. For b-hCG,
the sensitivity of the assay was\1 mlU/ml, and the intra-
and inter-assay CV values were 4 and 7.3 %, respectively.
For progesterone, the sensitivity of the assay was 0.045 ng/
ml, and the intra- and inter-assay CV values were 6.99 and
4.34 %, respectively. The sample concentrations were
calculated using a best-fit four-parameter logistic calibra-
tion curve (KCJunior; Bio-Tek). Each treatment was ana-
lyzed in ten wells, and each experiment was repeated three
times.
Protein isolation and Western blot analysis
Protein isolation and Western blot analysis were performed
as described previously [29]. The membranes were incu-
bated overnight at 4 C with the mouse monoclonal anti-
PPARc (sc-7273; Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA) that was diluted at 1:100 in TBS/Tween.
After incubation with the primary antibody, the membranes
were washed with TBST (0.02 M TBS and 0.02 % Tween
20) and incubated for 1 h with goat anti-mouse HRP-con-
jugated antibody (sc-2005; Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA) that was diluted at 1:500 in TBS/
Tween. The signals were detected by chemiluminescence
(ECL) using a Western Blotting Luminol Reagent (sc-2048,
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and
imaged using GeneSnap software and a G:Box Imaging
system. To confirm that the protein loading was the same
across the gel, theWestern blot membrane was cut into strips
and probedwith an anti-b-actin antibody as a loading control
(Sigma Chemical Co., St. Louis, MO, USA).
Caspase-3 activity
Caspase-3 activity was used as a marker for cell apoptosis
and was determined according to Nicholson et al. [30]. The
enzyme activity was measured with the AC-DEVD-pNA
colorimetric assay as previously described [31]. Briefly,
cultured cells were lysed on ice with a lysis buffer (50 nM
HEPES, pH 7.4, 100 nM NaCl, 0.1 % CHAPS, 1 nM
EDTA, 10 % glycerol, and 10 nM DTT). The reaction was
initiated by the addition of caspase-3 substrate Ac-DEVD-
pNA (N-acetyl-Asp-Glu-Val-Asp-p-nitroanilide; Sigma) to
a final concentration of 200 lM. The samples were incu-
bated in the dark at 37 C for 1 h. Then, the colorimetric
release of p-nitroaniline from the Ac-DEVD-pNA substrate
was recorded every 30 min and monitored continuously for
120 min at 405 nm in a microplate reader (Bio-Tek
ELx800). Cells that were treated with 1 nM staurosporine
were used as a positive control (Sigma, St Louis, MO,
USA). The data were analyzed with KCJunior (Bio-Tek
Instruments), normalized to the absorbance in vehicle-
treated cells, and expressed as the percent of con-
trol ± SEM of ten separate samples that were run in trip-
licate. The absorbance of the blanks, acting as no-enzyme
controls, was subtracted from each value. Because the
initial substrate concentration was subsaturating (200 lM),
only the data within the linear range of the reaction curve
provided a consistent measure of caspase-3 activity.
Identification of apoptotic cells
Apoptotic cells exhibit nuclear condensation and DNA
fragmentation that can be detected by ‘‘vital’’ staining with
Hoechst 33342 (Sigma, St Louis, MO, USA). For this pur-
pose, JEG-3 cells were seeded on coverslips that were set in
24-well plates at a density of 8 9 104/well and initially
cultured for 24 h to allow for attachment. The next day, the
mediumwas changed toDMEM that was supplementedwith
5 % charcoal-stripped FBS with the addition of 10 nM or
10 lM of TBBPA, and the cells were cultured for another
24 h. After this period, the cells were washed with PBS and
exposed to Hoechst 33342. Hoechst 33342 was diluted with
PBS and added to the medium to a final concentration of
10 lM. The cells were incubated for 15 min in an atmo-
sphere of 5 %CO2/95 % air at 37 C and then studied with a
fluorescence microscope (Nikon, Japan).
Statistical analysis
The data were presented as the mean ± SEM of three
independent experiments. Each treatment was repeated
three times in ten wells. Thus, the total number of repli-
cates was 30. The average of the repeats was used for
statistical calculations. Data were analyzed by one-way
analysis of variance (ANOVA). To determine the signifi-
cant differences, the means were compared between the
treated groups and the control group using Dunnett’s test
for multiple comparisons. Significance was indicated as




Increasing concentrations of TBBPA in the cultures of
JEG-3 cells affected progesterone secretion (Fig. 1).
TBBPA treatment for 24 h led to an increase in proges-
terone levels but was only significant in the micromolar
range (10 and 50 lM). However, 48 h of treatment with
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both nanomolar and micromolar doses resulted in signifi-
cant increases, with progesterone secretion ranging from
approximately 12–30 %. TBBPA treatment with 50 lM
seemed to be the most effective at increasing progesterone
levels by 2- to 3-fold compared with those of the vehicle
control (DMSO) at all of the time points. TBBPA at a
concentration of 100 lM decreased progesterone secretion
due to the dominant cytotoxic effect (up to 53 % LDH
leakage).
Caspase-3 activity and Hoechst 33342 staining
TBBPA at all of the tested doses significantly increased
caspase-3 activity compared with that of the vehicle control
(Fig. 2). The caspase-3 activity was dose-dependent up to
10 and 1 lM of TBBPA for 24 and 48 h, respectively. At
these concentrations, the average increase in caspase-3
activity was 1.8- to 2.5-fold after 48 h compared with that
observed after 24 h. After 72 h exposure to TBBPA, cas-
pase-3 activity reached the level compared to that of the
control cells, suggesting that the final phase of apoptosis
occurs upon damage to the cell membrane. The apoptotic
action of TBBPA was also confirmed by Hoechst 33342
staining (Fig. 3a–d). Morphological changes, as indicated
by bright blue fragmented nuclei, nuclear shrinkage, and
subsequent chromatin condensation into the periphery of
the nuclei, were identified as apoptotic bodies. The number
of apoptotic body increased in a dose-dependent manner.
Fig. 1 Time- and dose-
dependent effect of increasing
concentrations of TBBPA on
JEG-3 cells viability (line
graph) and progesterone
secretion (bar graph). Each
point represents the
mean ± SEM of three
independent experiments, each
of which consisted of ten
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Fig. 2 Time- and dose-
dependent effect of increasing
concentrations of TBBPA on
apoptosis in JEG-3 cells as
determined by caspase-3
activity. Cells treated with 1 nM
of staurosporine (STA) were
used as a positive control. Each
point represents the
mean ± SEM of three
independent experiments, each
of which consisted of ten




differences between control and
experimental groups
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b-hCG secretion
TBBPA at nanomolar and micromolar concentrations sig-
nificantly decreased b-hCG release by JEG-3 cells at all
culture time points (24–72 h) (Fig. 4). TBBPA-induced
decrease in b-hCG secretion ranged from 15 to 37 %
compared to control (vehicle-treated) cells. The highest
TBBPA dose (100 lM) showed a strong cytotoxic effect as
demonstrated by an increase in LDH release and a low
undetectable medium level of b-hCG.
Effect of the PPARc agonist GW1929 or antagonist
GW9662 on the TBBPA-induced decrease of b-hCG
secretion
48 h of treatment with TBBPA at concentrations of 10 nM
caused significant decreases in the b-hCG production of
approximately 31 %, compared with that of the vehicle
control (Fig. 5). However, after this time, co-treatment
with antagonist did not restore the TBBPA-mediated
decrease in the b-hCG level. In contrast, co-treatment with
antagonist and TBBPA led to a 1.9-fold decrease in b-hCG
production compared with that of TBBPA treatment alone.
Interestingly, treatment with antagonist alone caused a 1.5-
fold decrease in b-hCG secretion compared with that found
upon TBBPA treatment. Treatment with agonist also
reduced b-hCG secretion, but the effect was much greater
and resulted in a significant decrease that was approxi-
mately 2.3-fold higher than that of the TBBPA treatment.
Agonist as well as TBBPA reduced b-hCG release, but
both exhibited synergy with co-treatment.
Effect of TBBPA or/and GW1929 or GW9662
on the expression of PPARc in JEG-3 cells
The JEG-3 cell line that was used in this study was found to
express the PPARc protein, in agreement with previous
studies [32]. Immunoblot analyses showed that compared
with the control cells, TBBPA at concentrations of 10 nM
Fig. 3 a–d The effect of TBBPA (10 nM, 100 nM, and 10 lM) on
Hoechst 33342 staining in JEG-3 cell cultures, examined 48-h post-
treatment. a Control cells, b 10 nM TBBPA, c 100 nM TBBPA,
d 10 lM TBBPA. No typical apoptotic cells with light-colored
cytoplasm were observed in control group (a). Cells with bright














































































































Fig. 4 Time- and dose-
dependent effect of increasing
concentrations of TBBPA on
JEG-3 cells viability (line
graph) and b-hCG secretion
(bar graph). Each point
represents the mean ± SEM of
three independent experiments,
each of which consisted of ten
replicates per treatment group.
Data indicated with *p\ 0.05;
***p\ 0.001 (b-hCG
secretion) and ###p\ 0.001
(LDH release) reflects
statistically significant
differences between control and
experimental groups
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and 10 lM increased the expression of the PPARc protein
in JEG-3 cells after 3–72 h of exposure (Fig. 6a, b).
PPARc protein expression increased in a time-dependent
manner until 48 h and then slightly decreased at 72 h but
remained above the control level. For a subsequent anal-
ysis, we measured PPARc protein expression after TBBPA
treatment at a concentration of 10 nM and a single time
point of 48 h. To better understand the relationship
between PPARc protein expression and TBBPA treatment,
we used a PPARc agonist (GW1929) or antagonist
(GW9662). Immunoblot analyses demonstrated that 10 nM
TBBPA caused a 3.5-fold increase in the expression of the
PPARc protein compared with the control level (Fig. 7).
Interestingly, treatment with agonist alone also caused a
significant increase in PPARc protein expression compared
with that of the solvent control. Co-treatment with agonist
or antagonist caused a modest but insignificant increase in
the PPARc protein expression.
Discussion
TBBPA is widely used as a flame retardant, but it also has a
well-documented endocrine-related biological activity. In
particular, higher concentrations of TBBPA in infants
compared with their mothers [23] generate great concern
because there is a possibility that TBBPA might affect
placental function. In this study, we used the human
choriocarcinoma-derived placental JEG-3 cell line, which
is a reliable model in studies of placental function. This cell
line possesses many biological and biochemical charac-
teristics of syncytiotrophoblasts [32] and produces pla-
cental hormones [33, 34]. This study showed, for the first
time that TBBPA treatment disturbed the synthesis of
progesterone by placental cells, the impact of TBBPA on
the synthesis of progesterone by placental cells. Our results
indicate that TBBPA treatment affected progesterone
secretion at all time points compared with the control. An
increase in progesterone secretion was significant after
24 h of treatment with TBBPA in the micromolar range
and also after 48 h of treatment with TBBPA in the
nanomolar range. The results of our previous studies
demonstrated that TBBPA also exerted a marked stimula-
tory effect on estradiol secretion by JEG-3 cells [29].
Progesterone together with estradiol keeps the placenta
functioning properly. Estradiol regulates the uptake of LDL
particles, which is the first and rate-limiting step in pro-
gesterone synthesis [35]. These hormones mutually regu-
late each other in placenta steroidogenesis, which was
confirmed in two independent experiments. Wunsch et al.
[36] showed that the antiestrogen MER-25 and the aro-
matase inhibitor 4-OHA reduced progesterone production
in primary cultures of placental cells from pregnant woman
at term. Moreover, the marked reduction in progesterone
formation was reversed by the addition of estradiol. These
results agree with those reported by Shanker et al. [37] who
also observed a regulatory role of estradiol in progesterone
synthesis in primary cultures of first trimester human pla-
cental cells. Our findings, as well as those of other inves-
tigators, indicate that one mechanism of TBBPA-mediated
increase in progesterone secretion could be associated, at
least in part, with the ability of TBBPA to increase the
estradiol level. Furthermore, estradiol and progesterone
increase CYP11A1 mRNA in cultured human syncy-
tiotrophoblasts, which may suggest a positive feedback
mechanism from placental steroids [38, 39]. CYP11A1
catalyzed the side-chain cleavage of cholesterol, which is
rate-limiting in the synthesis of progesterone by the human
placenta [40]. Interestingly, Dankers et al. [41] also

























Fig. 5 The effect of TBBPA (10 nM) in the presence of PPARc
agonist GW1929 and antagonist GW9662 on b-hCG secretion in
JEG-3 cells after 48 h of exposure. Each point represents the
mean ± SEM of two independent experiments, each of which
consisted of ten replicates per treatment group. Data indicated with
***p\ 0.001 reflects statistically significant differences relative to
the control. Data indicated with ###p\ 0.001 reflects statistically
significant differences relative to TBBPA
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cytochrome P450scc (CYP11A1) gene expression in a
murine Leydig (Ma-10) cell line. CYP11A1 not only seems
to be the key regulator of steroidogenesis, but it may also
be involved in the induction of apoptosis [42]. In the pre-
sent investigation, the relationship between the CYP11A1
gene and the apoptosis of trophoblast cells was not
explored, but He et al. [43] investigated this issue. These
authors showed that the overexpression of CYP11A1 in the
trophoblast cell line HTR-8/SVneo induced cell apoptosis
through the activation of caspase-3 expression. Our data
revealed the proapoptotic effects of TBBPA in JEG-3 cells
via the induction of a prominent increase in caspase-3
activity. This stimulatory effect was observed after 24 and
48 h of treatment with TBBPA at doses of up to 10 and
Fig. 6 a, b The upper panel shows a representative Western blot of
PPARc protein levels in JEG-3 cells treated with TBBPA (10 nM and
10 lM) for 3, 6, and 12 h (a) and 24, 48, and 72 h (b). The lower
panel shows pooled data of three independent experiments. The
Western blot membrane was cut into strips and probed with an anti-b-
actin antibody to control the amounts for protein loading. PPARc
bands were quantified by densitometry. The results are shown as the
percentage of PPARc protein relative to the control. Data indicated
with **p\ 0.01 reflects statistically significant differences relative to
the control
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1 lM, respectively, compared with that of the vehicle
control. A 72-h exposure to TBBPA resulted in a level of
caspase-3 activity approximate to that of control cells,
suggesting that the final phase of apoptosis occurs fol-
lowing damage to the cell membrane. The apoptotic action
of TBBPA was also confirmed by Hoechst 33342 staining.
Although additional studies are required to determine the
mechanism of TBBPA action, our findings, as well as those
of He et al., provide valuable input into the molecular
mechanism of endocrine disruption in human placental
cells. The results of our study describing the effect of
TBBPA on the activation of caspase-3 can only be com-
pared with results from studies using different biological
models. So far, TBBPA at micromolar concentrations has
been shown to induce apoptosis in mouse primary neuronal
cell cultures [44], rat pheochromocytoma PC-12 [45] and
SH-SY5Y human neuroblastoma cells [46], and in Sertoli
cells [47]. In these studies, the proapoptotic action of
TBBPA occurred only at micromolar concentrations,
whereas even nanomolar concentrations were effective in
the studies presented above.
The data presented herein also demonstrate the adverse
effect of TBBPA on b-hCG secretion in JEG-3 cells,
resulting in a significantly decreased hormone level after
both short-term (24 and 48 h) and long-term (72 h)
exposure. An inhibitory effect was observed at a wide
range of TBBPA concentrations (1 nM–10 lM). TBBPA
at this range of concentrations did not affect JEG-3 cell
viability, whereas the level of b-hCG decreased as the time
of exposure increased. These results suggest that an altered
hormone level is associated with the effect of TBBPA on
b-hCG secretion. To the best of our knowledge, there have
been no reports on the action of TBBPA on b-hCG syn-
thesis in human placental cells. There are very few data
available regarding the modulation of b-hCG synthesis in
human placental cells by trialkyltin [48], DDT and its
metabolite [49] or TCDD [50]. These studies, however, do
not explain the molecular mechanism that is responsible for
the adverse effects on b-hCG secretion. Wo´jtowicz et al.
[49] suggested that a possible mechanism of hCG inhibi-
tion may involve the elevation of the progesterone level. A
dose-dependent progesterone inhibitory action on hCG
secretion or/and production was found in human term
placental explant culture [51, 52]. This hypothesis could
agree with our data, demonstrating a decreased b-hCG
level and increased progesterone level, but additional
experimental evidence is required.
It is clearly established that hCG gene expression is
regulated by PPARc [53]. It also has been postulated that
PPARc stimulates hCG synthesis and trophoblast
Fig. 7 The upper panel shows
a representative Western blot of
PPARc protein levels in JEG-3
cells treated with TBBPA
(10 nM), GW1929 (10 lM), co-
treated with TBBPA (10 nM)
and GW1929 (10 lM),
GW9662 (10 lM), co-treated
with TBBPA (10 nM) and
GW9662 (10 lM) for 48 h. The
lower panel shows pooled data
of three independent
experiments. The Western blot
membrane was cut into strips
and probed with an anti-b-actin
antibody to control the amounts
for protein loading. PPARc
bands were quantified by
densitometry. The results are
shown as the percentage of
PPARc protein relative to the
control. Data indicated with
***p\ 0.001 reflects
statistically significant
differences relative to the
control. Data indicated with
###p\ 0.001 reflects
statistically significant
differences relative to TBBPA
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differentiation [54, 55]. The results in our study showed
that impairment in b-hCG secretion is accompanied by
increased levels of the PPARc protein. An immunoblot
analysis demonstrated that after TBBPA treatment at
10 nM and 10 lM, PPARc protein expression increased in
a time-dependent manner until 48 h and then slightly
decreased at 72 h but remained above the control level.
Therefore, we hypothesized that in our study, PPARc is
involved in TBBPA-mediated decrease in b-hCG secretion.
PPARc involvement in the mechanism of TBBPA action
was demonstrated in NIH3T3-L1 preadipocytes and in
mouse neocortical cells. It has recently been reported that
PPARs are targets for TBBPA action [28, 44].
The JEG-3 cell line that was used in our study was found
to express the PPARc protein, in agreement with previous
studies [32]. Our data are the only to show the up-regula-
tion of PPARc protein expression after TBBPA exposure in
human placental cells. When JEG-3 cells were treated with
10 nM of TBBPA, PPARc protein expression increased
almost 3.5-fold compared with that of control cells. It is
noteworthy that TBBPA at 10 nM had a more profound
effect on PPARc expression than did a specific agonist
alone, which caused only a 2.5-fold increase. Co-treatment
of TBBPA with PPARc antagonist restored TBBPA-me-
diated increase in PPARc protein level. A similar results
were observed for co-treatment of TBBPA with PPARc
agonist. It is possible that both TBBPA and GW1929
competed for the same binding site on the receptor.
To explain the relationship between PPARc and b-hCG
secretion, the effect of selective PPARc antagonist
(GW9662) was examined. Although co-treatment with
GW9662 reversed the TBBPA-mediated increase in
PPARc protein expression and restored it to the control
level, it did not reverse the effect on b-hCG secretion.
According to b-hCG secretion, co-treatment with GW9662
potentiated an inhibitory effect of TBBPA, leading to a
decrease in b-hCG secretion to a level much lower than
that found in TBBPA treatment alone. Moreover, the effect
of GW9662 and TBBPA on b-hCG secretion was similar to
that of GW9662 alone. Our data also showed that treatment
with GW9662 alone caused an increase in the PPARc
protein level compared with that of the solvent control.
Similarly, Levytska et al. [56] documented an increase in
the PPARc protein level after treatment with T0070907, an
antagonist of this receptor, in BeWo choriocarcinoma cells.
Moreover, our results agree with those reported by
Levytska et al., who found that blocking PPARc activity
with T0070907 resulted in a significant downregulation in
b-hCG secretion by BeWo cells. It may suggest that a
negative-feedback mechanism regulates the self-expression
of PPARc protein.
The data presented herein demonstrated that although
TBBPA exerts some of its action via the activation of
PPARc, there are clearly alternate mechanisms that are
involved in its biological actions, particularly in a PPARc-
independent manner. Additional experiments are required
to verify this hypothesis. Considering the important role of
PPARc in placenta development and our findings that an
alteration in PPARc protein expression was accompanied
by decreased b-hCG levels at each time point, further
research is required to elucidate a possible role of PPARc
in TBBPA-mediated endocrine disrupting effects. The
available literature provides some evidence that an alter-
ation in the PPARc protein expression pattern may be
involved in different pathologies of the human placenta.
Holdsworth-Carson et al. [57] examined placentas in
pregnancies that were complicated with preeclampsia and
intrauterine growth restriction and demonstrated significant
increases in PPARc expression. Moreover, Fournier et al.
[26] suggested that the over-activation of the PPARc
receptor at the maternal-fetal interface could impair
implantation and placentation, thereby affecting embryonic
development.
In summary, our results demonstrate for the first time
that TBBPA is able to alter the progesterone and b-hCG
production of JEG-3 cells and revealed proapoptotic effects
via the induction of a prominent increase in caspase-3
activity. We also assessed the ability of TBBPA to alter
PPARc protein expression, which was accompanied by
decreased b-hCG levels. We speculate that TBBPA exerts
its endocrine disrupting properties through complex inter-
actions at the receptor level and could directly or indirectly
affect the regulation of b-hCG gene expression in tro-
phoblast, but a complete understanding the mechanism of
TBBPA action in placental cells will require further
experiments. However, the results are particularly inter-
esting because TBBPA affects placental cells at doses that
are equal to the exposure level in a general population.
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